Thinking of joining a study?

Register your interest

NCT02093065 | COMPLETED | Hemophilia A


Platelet Function in Patients With Hemophilia A
Sponsor:

Boston Children's Hospital

Information provided by (Responsible Party):

Alan D. Michelson

Brief Summary:

Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (\<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors. Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.

Condition or disease

Hemophilia A

Study Type : OBSERVATIONAL
Estimated Enrollment : 36 participants
Official Title : Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A
Actual Study Start Date : 2015-03
Estimated Primary Completion Date : 2018-06
Estimated Study Completion Date : 2020-02-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 2 Years to 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients with severe hemophilia A who are being prophylactically treated with FVIII.
  • * Age of at least 2 years.
  • * Bleeding history of at least 6 months.
  • * IRB-approved informed consent.
Exclusion Criteria
  • * Presence of FVIII inhibitors.
  • * Greater than 7 days since active bleeding.

Platelet Function in Patients With Hemophilia A

Location Details

NCT02093065


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

United States, Massachusetts

Boston Children's Hospital, Boston Hemophilia Center

Boston, Massachusetts, United States, 02115

Loading...